Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 9/20 | 0.43 |
| ▸ | TSHR | P16473 | 6/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.38 |
| ▸ | USP2 | O75604 | 4/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21214518 | 0.87 | CYP3A4 (0.37) | CYP3A4TSHRCYP2D6USP2HSD17B10 | |
| SCHEMBL19226671 | 0.85 | CYP3A4 (0.35) | CYP3A4CYP2C19HIF1A | |
| SCHEMBL15112835 | 0.84 | CYP3A4 (0.41) | CYP3A4TSHRCYP2D6USP2HSD17B10 | |
| SCHEMBL19978300 | 0.83 | HSD11B1 (0.33) | TSHRCYP2D6USP2HSD17B10CYP2C9 | |
| SCHEMBL24276408 | 0.82 | CYP2D6 (0.33) | CYP3A4TSHRCYP2D6USP2HSD17B10 | |
| SCHEMBL17886517 | 0.78 | USP2 (0.41) | CYP3A4TSHRCYP2D6USP2HSD17B10 | |
| SCHEMBL22016879 | 0.77 | — | — | |
| SCHEMBL1753469 | 0.77 | USP2 (0.53) | CYP3A4TSHRCYP2D6USP2HSD17B10 | |
| SCHEMBL13050810 | 0.77 | USP2 (0.44) | CYP3A4TSHRCYP2D6USP2HSD17B10 | |
| SCHEMBL21100795 | 0.76 | HIF1A (0.34) | TSHRHIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170304305-A1 | QUINAZOLINE DERIVATIVES SUBSTITUTED BY ANILINE, PREPARATION METHOD AND USE THEREOF | XUANZHU PHARMA CO LTD (CN) | 2017-10-26 | — | — | US | disclosed |
| US-9730934-B2 | Quinazoline derivatives substituted by aniline, preparation method and use thereof | Xuanzhu Pharma Co., Ltd. (CN) | 2017-08-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170304305-A1 | QUINAZOLINE DERIVATIVES SUBSTITUTED BY ANILINE, PREPARATION METHOD AND USE THEREOF | NQO2, CHRM1, CHRM2 | CYP3A4 57/4885TSHR 1092/4885CYP2D6 190/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.